Evidence map›Paper›PMID 25582624›Full record

ArticleProstate cancer and prostatic diseases2015

Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system.

T J Daskivich, L Kwan, A Dash, M S Litwin

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cancer Progress and Priorities: Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. African-American Prostate Cancer Disparities.Current urology reports · 2017
    Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

T J Daskivich1] Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA [2] Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, CA, USA.
L KwanJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
A DashDepartment of Urology, University of Washington, Seattle, Washington, USA.
M S Litwin1] Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA [2] Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, CA, USA [3] Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA [4] Department of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USUniversity of Washington · USWest Los Angeles College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAfrican-American men with prostate cancer typically have higher tumor risk at diagnosis, lower rates of surgical treatment and poorer cancer-specific survival compared with Caucasians. Receipt of care within the Veterans Affairs (VA) healthcare system may reduce barriers that influence these disparities.

methodsWe sampled 1258 men with nonmetastatic prostate cancer diagnosed at the Greater Los Angeles and Long Beach VA Medical Centers between 1998 and 2004. We compared African Americans and Caucasians with respect to tumor characteristics using ordinal logistic regression, treatment choice across substrata of tumor risk using logistic regression, and cancer-specific and other-cause mortality using competing risks regression analysis.

resultsMultivariate ordinal logistic regression revealed no significant differences in odds of higher tumor risk (odds ratio (OR) 1.22, 95% confidence interval (CI) 0.98-1.53, P=0.08), Gleason score (OR 0.90, 95% CI 0.7-1.16, P=0.4) or clinical stage (OR 1.04, 95% CI 0.79-1.38, P=0.8) for African Americans compared with Caucasians. African-American men had similar odds of aggressive treatment as did Caucasians for low-risk (OR 0.92, 95% CI 0.57-1.53, P=0.8), intermediate-risk (OR 0.75, 95% CI 0.44-1.26, P=0.3) and high-risk disease (OR 0.87, 95% CI 0.52-1.44, P=0.6). In competing risks regression analysis, African Americans had a lower but nonsignificant hazard of cancer-specific mortality compared with Caucasians (sub-hazard ratio 0.6, 95% CI 0.28-1.26, P=0.2) and nearly identical risk of other-cause mortality (sub-hazard ratio 0.98, 95% CI 0.78-1.22, P=0.8).

conclusionsWe found no significant differences in tumor burden, treatment choice or survival outcomes between African Americans and Caucasians cared for in the equal-access VA Healthcare setting.

Indexed as

Black or African AmericanSEER ProgramAgedFemaleHealthcare DisparitiesHumansMaleMiddle AgedNeoplasm GradingProstatic NeoplasmsTumor BurdenWhite People

Identifiers

PMID25582624
OpenAlexW2042821311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.